Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132526) titled 'The efficacy and safety of Upadacitinib in the treatment of SAPHO syndrome' on Sept. 15.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Shanghai Sixth People's Hospital

Condition: SAPHO syndrome

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2025-09-29

Target Sample Size: Upadacitinib:15;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=336048

Published by HT Digital Content Services with permission from Health Daily Digest....